欧洲生技药品CDMO 市场：按细胞类型、分子类型和国家：分析和预测（2023-2032 年）

欧洲生技药品CDMO 市场规模预计将从 2023 年的 64.8 亿美元增至 2032 年的 216.1 亿美元，2023-2032 年预测期间复合年增长率为 14.32%。

这一市场轨迹显示它将对医药保健产生变革性影响。巧妙应对复杂监管并拥抱技术创新的公司将会取得巨大成功。

在单株抗体、疫苗以及细胞和基因疗法等生物疗法需求不断增长的推动下，欧洲生技药品CDMO 市场正在经历强劲成长。慢性病的增加、生物学的重大发展以及药物开发和製造过程外包趋势的上升是推动市场的主要因素。欧洲 CDMO 正在投资最先进的设施和最尖端科技，以提高产能并满足严格的监管标准。策略联盟和伙伴关係也不断增加，使 CDMO 能够提供从初始开发到商业生产的全面服务。凭藉政府的大力支持和成熟的生物製药产业，欧洲生技药品CDMO 市场有望持续扩张和创新。

该报告考察了欧洲生技药品CDMO 市场，并提供了市场概况，包括按细胞类型、分子类型和国家分類的趋势，以及进入市场的公司概况。

目录

执行摘要

第一章 范围和定义

第二章市场：产业展望

• 趋势：当前和未来的影响评估
• 市场足迹
• 供应链概览
• 专利分析
• 监管状况
• 外包给 CDMO 时要考虑的因素
• 市场动态概览
• 市场驱动因素
• 市场限制因素
• 市场机会

第三章全球生技药品CDMO市场，按地区，2022-2032

• 区域概况
• 促进因素和抑制因素
• 欧洲
  • 欧洲生技药品CDMO 市场（按细胞类型）
  • 欧洲生技药品CDMO 市场（按分子类型）
  • 欧洲（按国家/地区）

第四章市场－竞争基准化分析与公司概况

• 竞争格局
• Boehringer Ingelheim International GmbH
• Lonza
• Novartis AG

Introduction to Europe Biologics CDMO Market

The Europe biologics CDMO market is projected to reach $21.61 billion by 2032 from $6.48 billion in 2023, growing at a CAGR of 14.32% during the forecast period 2023-2032. The market's trajectory indicates a transformative impact on pharmaceutical care. Companies that skillfully navigate regulatory complexities and adopt technological innovations are well-positioned for significant success.

Market Introduction

The Europe Biologics CDMO market is experiencing robust growth, driven by increasing demand for biologic therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies. The rise in chronic diseases, advancements in biology, and the growing trend of outsourcing drug development and manufacturing processes are key factors propelling the market. European CDMOs are investing in state-of-the-art facilities and cutting-edge technologies to enhance production capabilities and meet stringent regulatory standards. Strategic collaborations and partnerships are also on the rise, enabling CDMOs to offer comprehensive services from early development to commercial manufacturing. With strong government support and a well-established biopharmaceutical sector, the Europe Biologics CDMO market is poised for sustained expansion and innovation.

Market Segmentation:

Segmentation 1: by Cell Type

• Mammalian
• Microbial and Others

Segmentation 2: by Molecule Type

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Hormones
• Others

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe biologics CDMO market (by molecule type) has been segmented into different types of molecules used in developing biologics. Moreover, the study provides the reader with a detailed understanding of the different cell types and indications as well.

Growth/Marketing Strategy: The market growth and marketing strategy of biologics CDMO market revolves around a combination of technical excellence, strategic collaborations, and market positioning. CDMOs leverage their specialized expertise in bioprocessing and manufacturing to offer comprehensive solutions to biopharmaceutical companies.

Competitive Strategy: Key players in the Europe biologics CDMO market have been analyzed and profiled in the study, including CDMOs involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

• Boehringer Ingelheim Group
• Lonza Group
• NOVARTIS AG

Table of Contents

Executive Summary

1 Scope and Definition

• 1.1 Market Definition
• 1.2 Key Questions Answered in the Report
• 1.3 Analyst and Forecast Note

2 Markets: Industry Outlook

• 2.1 Trends: Current and Future Impact Assessment
  • 2.1.1 Trend 1 - Increasing Biomanufacturing Capacity
  • 2.1.2 Trend 2 - Single-use Bioprocessing Equipment
  • 2.1.3 Trend 3 - Trend Toward Personalized Medicine
• 2.2 Market Footprint
• 2.3 Supply Chain Overview
• 2.4 Patent Analysis
• 2.5 Regulatory Landscape
• 2.6 Factors Considered While Outsourcing To CDMO
• 2.7 Market Dynamics Overview
• 2.8 Market Drivers
• 2.9 Market Restraints
• 2.10 Market Opportunities

3 Global Biologics CDMO Market, by Region, 2022-2032

• 3.1 Regional Summary
• 3.2 Drivers and Restraints
• 3.3 Europe
  • 3.3.1 Europe Biologics CDMO Market, by Cell Type
  • 3.3.2 Europe Biologics CDMO Market, by Molecule Type
  • 3.3.3 Europe (by Country)
    • 3.3.3.1 Germany
      • 3.3.3.1.1 Germany Biologics CDMO Market, by Cell Type
      • 3.3.3.1.2 Germany Biologics CDMO Market, by Molecule Type
    • 3.3.3.2 U.K.
      • 3.3.3.2.1 U.K. Biologics CDMO Market, by Cell Type
      • 3.3.3.2.2 U.K. Biologics CDMO Market, by Molecule Type
    • 3.4.3.3 France
      • 3.4.3.3.1 France Biologics CDMO Market, by Cell Type
      • 3.4.3.3.2 France Biologics CDMO Market, by Molecule Type
    • 3.4.3.4 Italy
      • 3.4.3.4.1 Italy Biologics CDMO Market, by Cell Type
      • 3.4.3.4.2 Italy Biologics CDMO Market, by Molecule Type
    • 3.4.3.5 Spain
      • 3.4.3.5.1 Spain Biologics CDMO Market, by Cell Type
      • 3.4.3.5.2 Spain Biologics CDMO Market, by Molecule Type
    • 3.4.3.6 Rest-of-Europe
      • 3.4.3.6.1 Rest-of-Europe Biologics CDMO Market, by Cell Type
      • 3.4.3.6.2 Rest-of-Europe Biologics CDMO Market, by Molecule Type

4 Markets - Competitive Benchmarking & Company Profiles

• 4.1 Competitive Landscape
• 4.2 Boehringer Ingelheim International GmbH
• 4.3 Lonza
• 4.4 Novartis AG

Research Methodology